Screening for primary aldosteronism in the diabetic population: a cohort study

Primary aldosteronism (PA) is the most common endocrine cause of hypertension. It is associated with higher cardio‐metabolic risk than essential hypertension. Hypertension is common in patients with type 2 diabetes who carry increased cardiovascular risk; however, it is unknown how frequently they are tested for PA.

[1]  J. Saito,et al.  Impact of primary aldosteronism on renal function in patients with type 2 diabetes , 2020, Journal of diabetes investigation.

[2]  P. Hopkins,et al.  The Unrecognized Prevalence of Primary Aldosteronism , 2020, Annals of Internal Medicine.

[3]  Qifu Li,et al.  Primary Aldosteronism in Patients in China With Recently Detected Hypertension. , 2020, Journal of the American College of Cardiology.

[4]  M. Young,et al.  Primary aldosteronism is a public health issue: challenges and opportunities , 2020, Journal of Human Hypertension.

[5]  Katsutoshi Takahashi,et al.  Diabetes mellitus itself increases cardio-cerebrovascular risk and renal complications in primary aldosteronism. , 2020, The Journal of clinical endocrinology and metabolism.

[6]  Wei Liu,et al.  Determining the Prevalence of Primary Aldosteronism in Patients With New-Onset Type 2 Diabetes and Hypertension. , 2020, The Journal of clinical endocrinology and metabolism.

[7]  G. Adler,et al.  Primary Aldosteronism Decreases Insulin Secretion and Increases Insulin Clearance in Humans , 2020, Hypertension.

[8]  T. Kotchen.  Impaired Glucose Tolerance in Primary Aldosteronism: Mechanism(s) and Clinical Implications. , 2020, Hypertension.

[9]  Jun Yang,et al.  Screening for primary aldosteronism: How to adjust existing antihypertensive medications to avoid diagnostic errors. , 2020, Australian journal of general practice.

[10]  J. Leppert,et al.  Screening Rates for Primary Aldosteronism in Resistant Hypertension , 2020, Hypertension.

[11]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020 , 2019, Diabetes Care.

[12]  P. Fuller,et al.  Current pattern of primary aldosteronism diagnosis: Delayed and complicated , 2018, Australian journal of general practice.

[13]  W. Hsueh,et al.  Renin‐Angiotensin‐Aldosterone System, Glucose Metabolism and Incident Type 2 Diabetes Mellitus: MESA , 2018, Journal of the American Heart Association.

[14]  M. Sone,et al.  Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism , 2018, The Journal of clinical endocrinology and metabolism.

[15]  M. Stowasser,et al.  Is it time to screen all patients with hypertension for primary aldosteronism? , 2018, The Medical journal of Australia.

[16]  Gang Liu,et al.  A cohort study , 2018 .

[17]  John R. Petrie,et al.  Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms , 2017, The Canadian journal of cardiology.

[18]  K. Yamashiro,et al.  Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study , 2017, Journal of clinical medicine research.

[19]  U. Lindblad,et al.  Prevalence of primary aldosteronism among patients with type 2 diabetes , 2017, Clinical endocrinology.

[20]  F. Veglio,et al.  Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. , 2017, Journal of the American College of Cardiology.

[21]  F. Veglio,et al.  Guidelines for primary aldosteronism: uptake by primary care physicians in Europe , 2016, Journal of hypertension.

[22]  J. Lenders,et al.  Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. , 2016, The Journal of clinical endocrinology and metabolism.

[23]  W. Young,et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[24]  A. Correa,et al.  Aldosterone, Renin, and Diabetes Mellitus in African Americans: The Jackson Heart Study. , 2016, The Journal of clinical endocrinology and metabolism.

[25]  P. Tchounwou,et al.  The Renin-Angiotensin-Aldosterone System in Vascular Inflammation and Remodeling , 2014, International journal of inflammation.

[26]  R. Zietse,et al.  Test characteristics of the aldosterone-to-renin ratio as a screening test for primary aldosteronism , 2014, Journal of hypertension.

[27]  T. Yanase,et al.  Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension. , 2013, Endocrine journal.

[28]  F. Beuschlein,et al.  Aldosterone excess impairs first phase insulin secretion in primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.

[29]  K. Sharma,et al.  The role of aldosteronism in causing obesity-related cardiovascular risk. , 2010, Cardiology clinics.

[30]  R. Holle,et al.  Is Primary Aldosteronism Associated with Diabetes Mellitus? Results of the German Conn's Registry , 2010, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[31]  G. Umpierrez,et al.  Primary Aldosteronism in Diabetic Subjects With Resistant Hypertension , 2008, Diabetes Care.

[32]  M. Ermani,et al.  Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. , 2006, The Journal of clinical endocrinology and metabolism.

[33]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[34]  P. Raskin,et al.  Management of hypertension in diabetes. , 1992, Endocrinology and metabolism clinics of North America.

[35]  THE ROYAL AUSTRALIAN COLLEGE OF GENERAL PRACTITIONERS , 1974 .

[36]  T. Fahey,et al.  Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. , 2019, Surgery.

[37]  Fiorenzo Gaita,et al.  Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. , 2018, The lancet. Diabetes & endocrinology.

[38]  A. Thai,et al.  Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism , 2010, Diabetes & vascular disease research.